Aufklappen
Schliessen
Branche BiotechnologieAktienmarkt Sonstige |
|
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
| Leser | Medien | |
|---|---|---|---|---|
| Mi | Alligator Bioscience reports Q1 results | - | Seeking Alpha | |
► Artikel lesen | ||||
| Mi | The Nomination Committee's Proposal for the Annual Shareholders' Meeting in Alligator Bioscience AB (publ) | 4 | PR Newswire | |
| LUND, Sweden, April 17, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the Nomination Committee in Alligator Bioscience has presented its proposal... ► Artikel lesen | ||||
| Mi | Alligator Bioscience AB (publ) Interim Report January-March 2019 | 5 | PR Newswire | |
| First patient dosed in Phase I clinical study of ATOR-1015
STOCKHOLM, April 17, 2019 /PRNewswire/ -- Significant events January-March
First patient dosed in Phase I clinical... ► Artikel lesen | ||||
| Jetzt News-Alert zur ALLIGATOR BIOSCIENCE Aktie erhalten | LYNX | |||
► Artikel lesen | ||||
| 10.04. | Alligator Bioscience to Present New Preclinical Data on ATOR-1015 at PEGS Boston | 2 | PR Newswire | |
| LUND, Sweden, April 10, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that Chief Medical Officer Charlotte Russell, MD, PhD, will give an oral presentation... ► Artikel lesen | ||||
| 02.04. | Alligator Bioscience: New Preclinical Data for ATOR-1144 Demonstrate Potential for Activation of Both the Innate and the Adaptive Immune System, as well as Direct Anti-tumor Effects | 4 | PR Newswire | |
| LUND, Sweden, April 2, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), today announce that new preclinical data on the drug candidate ATOR-1144 will be presented at the... ► Artikel lesen | ||||
| 22.03. | Alligator Bioscience's Annual Report 2018 Published | 2 | PR Newswire | |
| LUND, Sweden, March 22, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy... ► Artikel lesen | ||||
| 18.03. | Alligator Bioscience: New Preclinical Data Demonstrate Strong Anti-tumor Effects for the 4-1BB Antibody ATOR-1017 | 4 | PR Newswire | |
| LUND, Sweden, March 18, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX), today announce that they will present preclinical data for the drug candidate ATOR-1017 at the... ► Artikel lesen | ||||
| 07.03. | Alligator Bioscience: First Patient Dosed in Phase I study of ATOR-1015 | 31 | PR Newswire | |
| Dose-escalation study commences with first-in-class bispecific CTLA-4 antibody
LUND, Sweden, March 7, 2019 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces... ► Artikel lesen | ||||
| 14.02. | Alligator Bioscience reports Q4 results | - | Seeking Alpha | |
► Artikel lesen | ||||
| 14.02. | Alligator Bioscience AB Year-end Report 2018 | 1 | PR Newswire | |
| STOCKHOLM, Feb. 14, 2019 /PRNewswire/ --
Significant events October-December
The Swedish MPA (Medical Products Agency) approved start of Phase I clinical trial of ATOR-1015. New... ► Artikel lesen | ||||
| 12.02. | Alligator Bioscience to Host Conference Call to Provide Year-end Report 2018 Business Update | 1 | PR Newswire | |
| STOCKHOLM, Feb. 12, 2019 /PRNewswire/ --
Alligator Bioscience (Nasdaq Stockholm: ATORX) - On 14 February 2019, at 08:00 a.m. CET, Alligator Bioscience will publish its report for the... ► Artikel lesen | ||||
| 29.01. | Alligator Bioscience Publishes Clinical Phase I Data for ADC-1013 in the International Journal of Cancer | 4 | PR Newswire | |
| First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies
LUND, Sweden, Jan. 29, 2019 /PRNewswire/ -- Alligator Bioscience... ► Artikel lesen | ||||
| 07.01. | Alligator Bioscience Launches RUBY, a Novel Concept in Bispecific Antibody Formats | 4 | PR Newswire | |
| Priority filling submitted
RUBY bispecific concept has been developed to achieve an outstanding stability, manufacturability and shorter development timelines
LUND, Sweden, Jan.... ► Artikel lesen | ||||
| 11.12.18 | Alligator Bioscience Starts Clinical Phase I Study With ATOR-1015 | 4 | PR Newswire | |
| A first-in-class bispecific CTLA-4 antibody
LUND, Sweden, Dec. 11, 2018 /PRNewswire/ -- Alligator Bioscience AB (Nasdaq Stockholm: ATORX) today announces that regulatory approvals... ► Artikel lesen | ||||
| 10.12.18 | Frontier - A Magazine about Alligator Bioscience and Immuno-oncology | 2 | PR Newswire | |
| STOCKHOLM, Dec 10, 2018 /PRNewswire/ -- The science behind the Nobel Prizes in Medicine and Chemistry is the core in Alligator's research and development
Read the full magazine through... ► Artikel lesen | ||||
| 09.11.18 | Alligator Bioscience and Aptevo Therapeutics Present New Preclinical Data for ALG.APV-527 at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting | 4 | PR Newswire | |
| Data Show That ALG.APV-527 Selectively Activates and Enhances Tumor-directed T-cell and Natural Killer (NK) Cell Responses
Targets 5T4 Cancer Antigen Present on Many Types of Solid... ► Artikel lesen | ||||
| 07.11.18 | Alligator Bioscience to Receive Million-dollar Payments - AbClon Partner Exercises Option | 4 | PR Newswire | |
| LUND, Sweden, Nov. 7, 2018 /PRNewswire/ --
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that it will receive payments of more than USD 3.5 million under its collaboration... ► Artikel lesen | ||||
| 30.10.18 | Alligator Bioscience Expands Pipeline: Preclinical Development Initiated for the Candidate Drug ATOR-1144 | 5 | PR Newswire | |
| LUND, Sweden, Oct. 30, 2018 /PRNewswire/ --
Alligator Bioscience AB (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy... ► Artikel lesen | ||||
| 26.10.18 | Alligator Bioscience reports Q3 results | - | Seeking Alpha | |
► Artikel lesen | ||||
| 26.10.18 | Alligator Bioscience AB Interim Report January-September 2018 | 1 | PR Newswire | |
| STOCKHOLM, Oct. 26, 2018 /PRNewswire/ -- The science behind the Nobel Prizes in Medicine and Chemistry constitutes the core in Alligator's research and development.
Significant events... ► Artikel lesen | ||||
Seite:
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | |
|---|---|---|---|---|
| BB BIOTECH | 59,75 | -0,33 % | Münchener Rück, BB Biotech und Allianz: 3 starke Aktienrückkäufer! | |
| Wenn es um das Thema "Kapitalrückführungen" geht, scheiden sich oft die Geister. Viele Investoren neigen dazu, vor allem auf starke Dividendenausschütter zu setzen. Durch die regelmäßigen Ausschüttungen... ► Artikel lesen | ||||
| PAION | 2,22 | +0,91 % | Paion-CFO Omari: "Extrem wichtiger Meilenstein" | |
| Mit etwas Verzögerung hat der Paion-Partner Cosmo Pharmaceuticals Anfang April die Zulassung für Remimazolam in der Indikation Kurzsedierung in den USA bei der FDA eingereicht. Damit machen die Aachener... ► Artikel lesen | ||||
| AGENNIX | 0,005 | 0,00 % | DGAP-Adhoc: Agennix AG i.L.: Genehmigung Schlussrechnung / Ankündigung Beendigung Börsennotierung (deutsch) | |
| Agennix AG i.L.: Genehmigung Schlussrechnung / Ankündigung Beendigung Börsennotierung
DGAP-Ad-hoc: Agennix AG i.L. / Schlagwort(e): Hauptversammlung/Delisting
Agennix AG i.L.: Genehmigung Schlussrechnung... ► Artikel lesen | ||||
| MOLOGEN | 3,41 | -3,94 % | Mologen: Diese Information lässt die Aktie steigen | |
| Als gäbe es keine Querelen im Hintergrund, marschiert die Mologen-Aktie (WKN: A2LQ90) heute weiter nach oben. Gestern veröffentlichte der Krebsforscher weitere "eindrucksvolle Daten" zum potenziellen... ► Artikel lesen | ||||
| EXPEDEON | 0,894 | -0,67 % | Expedeon: Veränderung im Aufsichtsrat | |
| Cristina Garmendia Mendizabal legt den Posten der Aufsichtsratsvorsitzenden von Expedeon zum 4. April nieder. Sie verlässt zudem das Gremium. Zunächst übernimmt Joseph Fernandez, der bisherige stellvertretende... ► Artikel lesen | ||||
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von
Nachrichten • Aktienkurse • DAX • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer | Datenschutz • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage